ArticleTechnology in cancer research & treatment
Evaluation of Stimulated Raman Histology as a Novel Method for Pathologic Examination of Urothelial Carcinoma With Unprocessed, Fresh Bladder Cancer Tissue.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionStimulated Raman histology (SRH) is a recent microscopic technique allowing real-time, label free, high-resolution microscopic images of unprocessed, unsectioned tissue. Tissue samples are imaged in the operating room using a mobile SRH microscope, visualizing histology within minutes.MethodsAim of this prospective first in human feasibility study was to evaluate the use of SRH to identify bladder cancer (BCa) and to test whether a histopathological grading between low- and high-grade tumors can be determined. Therefore, patients with suspicion of BCa, who underwent transurethral resection of bladder tumor were included. Suspicious papillary tissue was resected and subsequently scanned with an SRH microscope (NIO, Invenio Imaging Inc.). After a 10-sample training set, pathologists were tested on a 30-sample test set. Images which were initially classified wrong were re-evaluated within a consensus conference.ResultsThe scanning time was less than 180 seconds for all tissues samples. Individual pathologists' overall combined accuracy (CA) for interpretation of low and high grade SRH images was 76.5 % [95% confidence interval (CI): 65.8-85.3]. After the consensus conference pathologists' overall CA for interpretation of low and high grade SRH images was 96.3 % [95% CI: 89.6-99.2], respectively. The sensitivity for the identification of high-grade tumors was between 66.0 % and 66.7 % before the consensus conference, increasing to 100 % after pathologic consensus. The specificity of the three pathologists was between 83.3 % and 100 %. After the consensus conference, the specificity was on average 91.7 %.ConclusionAfter further investigations, including the testing against benign tissue, SRH might be a reliable point of care-technique to produce high-resolution images of unprocessed bladder tumors, allowing histopathological identification of BCa. Low- and high-grade tumors can be accurately discriminated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.